Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair

Lyra Therapeutics, Inc.

Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.
Dr. Waksal eligible for severance per employment agreement upon signing separation and release.
Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.
Jim Tobin remains as Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.